MedTrace Logo

Immunogenicity of One Dose of Gardasil and One Dose of Gardasil-9

NCT03431246 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2018-02-13

No results posted yet for this study

Summary

This study will assess the immunogenicity of one dose of Gardasil and one dose of Gardasil-9

Conditions

  • Human Papillomavirus Vaccines

Interventions

BIOLOGICAL

Gardasil and Gardasil-9

All subjects will receive one dose of Gardasil-9. Blodd samples for serological testing will be collected just before and one month post Gardasil-9 administration.

Sponsors & Collaborators

Principal Investigators

  • Gaston DeSerres, MD, PhD · Quebec Public Health Institute

Study Design

Allocation
NA
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
12 Years
Max Age
18 Years
Sex
FEMALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-10-01
Primary Completion
2016-11-05
Completion
2016-12-05

Countries

  • Canada

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03431246 on ClinicalTrials.gov